Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 6Recruiting 1

Sponsor Class

OTHER 4NIH 2

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6

Conditions

Leukemia 42Lymphoma 33Melanoma 32Breast Neoplasms 31Leukemia, Myeloid, Acute 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia, Lymphocytic, Chronic, B-Cell 23Lymphoma, Non-Hodgkin 22Multiple Myeloma 21Lymphoma, Follicular 21Myelodysplastic Syndromes 19Prostatic Neoplasms 18Neuroblastoma 18Lymphoma, Mantle-Cell 17Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myeloid, Chronic-Phase 16Hodgkin Disease 15Neoplasms, Plasma Cell 14Lymphoma, Large-Cell, Immunoblastic 14Ovarian Neoplasms 13Lung Neoplasms 13Congenital Abnormalities 13Lymphoma, B-Cell, Marginal Zone 12Leukemia, Myeloid, Accelerated Phase 12Carcinoma, Non-Small-Cell Lung 12Burkitt Lymphoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Glioblastoma 11Carcinoma, Ovarian Epithelial 11Colorectal Neoplasms 10

Interventions

Ipilimumab 16incomplete Freund's adjuvant 9Nivolumab 9sargramostim 6Temozolomide 6Dacarbazine 6montanide ISA 51 5MART-1 Antigen 5Blood Specimen Collection 5pembrolizumab 4Ranibizumab 4Melphalan 4Interleukin-2 4Carboplatin 4CTLA-4 Antigen 4Thalidomide 3Surveys and Questionnaires 3MAGEA3 protein, human 3Granulocyte-Macrophage Colony-Stimulating Factor 3AZD 6244 3sotrastaurin 2relatlimab 2gp100 Melanoma Antigen 2fludarabine phosphate 2fludarabine 2entinostat 2aflibercept 2Taxes 2Sunitinib 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Uveal Melanoma × sargramostim × Clear all
NCT01989572 2020-07-07

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Completed
815 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00471471 2017-06-22

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

University of Pittsburgh

Phase 1 Completed
22 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00089063 2015-04-15

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00089206 2014-12-19

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

University of Virginia

Phase 2 Completed
7 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00089219 2014-11-20

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

University of Virginia

Phase 1/2 Completed
39 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00031733 2014-05-22

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

University of Southern California

Phase 2 Completed
60 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡